Patterns of Progression in Metastatic Estrogen Receptor Positive Breast Cancer: An Argument for Local Therapy

Table 3

Univariate analysis of clinical factors potentially associated diffuse disease progression.

	Patients with limited disease progression	Patients with diffuse disease progression
Age
<65	56%	60%	0.95
≥65	44%	40%
Phenotype
Her2(+)	26%	16%	<0.04
Her2(−)	74%	84%
Time to metastasis
≤6 months from initial Dx	50%	58%	0.85
>6 months from initial Dx	50%	42%
Longest time to progression
≤12 months	50%	42%	0.85
>12 months	50%	58%
# of metastatic sites
≤6 sites of disease	44%	20%	<0.04
>6 sites of disease	56%	80%
Disease site
Bone	47%	70%	<0.02
Other	53%	30%

displaying oligoprogression or oligometastases with progression at least once in their disease course.